tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Charles Duncan, 522 are a BUY (92.88%), 40 are a HOLD (7.12%).
Analyst Charles Duncan, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 50.42% that have a potential upside of 50.24% achieved within 349 days.
Charles Duncan’s has documented 1,066 price targets and ratings displayed on 79 stocks. The coverage is on Healthcare, Industrials, Technology, Basic Materials sectors.
Most recent stock forecast was given on OVID, Ovid Therapeutics at 09-Oct-2026.
Analyst best performing recommendations are on CLVS (CLOVIS ONCOLOGY).
The best stock recommendation documented was for RETA (REATA PHARMACEUTICALS) at 7/24/2023. The price target of $145 was fulfilled within 4 days with a profit of $35.33 (32.21%) receiving and performance score of 80.54.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 23-Jun-2025
$36
$16.88 (88.28%)
$37
11 days ago
(08-Oct-2026)
1/10 (10%)
$16.42 (83.86%)
173
Buy Since 15-Dec-2025
$33
$13.88 (72.59%)
$37
24 days ago
(25-Sep-2026)
0/3 (0%)
$12.32 (59.57%)
Buy Since 17-Apr-2025
$34
$14.88 (77.82%)
$36
24 days ago
(25-Sep-2026)
4/6 (66.67%)
$13.32 (64.41%)
144
Buy Since 25-Sep-2025
$31
$11.88 (62.13%)
$38
24 days ago
(25-Sep-2026)
1/4 (25%)
$10.32 (49.90%)
831
Buy Since 28-Feb-2024
$35
$15.88 (83.05%)
$41
24 days ago
(25-Sep-2026)
9/15 (60%)
$14.32 (69.25%)
393
Which stock is Charles Duncan most bullish on?
Which stock is Charles Duncan most reserved on?
What Year was the first public recommendation made by Charles Duncan?
